A
Alexander Kiani
Researcher at Dresden University of Technology
Publications - 102
Citations - 6173
Alexander Kiani is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: FOLFIRI & Cetuximab. The author has an hindex of 33, co-authored 95 publications receiving 5286 citations. Previous affiliations of Alexander Kiani include University of Freiburg & Harvard University.
Papers
More filters
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Röllig,Hubert Serve,Andreas Hüttmann,Richard Noppeney,Carsten Müller-Tidow,Utz Krug,Claudia D. Baldus,Christian Brandts,Volker Kunzmann,Hermann Einsele,Alwin Krämer,Kerstin Schäfer-Eckart,Andreas Neubauer,Andreas Burchert,Aristoteles Giagounidis,Stefan W. Krause,Andreas Mackensen,Walter E. Aulitzky,Regina Herbst,Mathias Hänel,Alexander Kiani,Norbert Frickhofen,Johannes Kullmer,Ulrich Kaiser,Hartmut Link,Thomas Geer,A. Reichle,Christian Junghanß,Roland Repp,Frank Heits,Heinz Dürk,Jana Hase,Ina-Maria Klut,Thomas Illmer,Martin Bornhäuser,Markus Schaich,Stefani Parmentier,Martin Görner,Christian Thiede,Malte von Bonin,Johannes Schetelig,Michael Kramer,Wolfgang E. Berdel,Gerhard Ehninger +43 more
TL;DR: This randomised, double-blind, placebo-controlled, phase 2 trial investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukaemia aged 60 years or younger.
Journal ArticleDOI
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Uwe Platzbecker,Martin Wermke,Jörgen Radke,Uta Oelschlaegel,F Seltmann,Alexander Kiani,Ina-Maria Klut,Holger Knoth,Christoph Röllig,Johannes Schetelig,Brigitte Mohr,Xina Graehlert,Gerhard Ehninger,Martin Bornhäuser,Christian Thiede +14 more
TL;DR: In this article, the authors evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Sebastian Stintzing,Sebastian Stintzing,Dominik Paul Modest,Dominik Paul Modest,Lisa Rossius,Markus M. Lerch,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Swantje Held,Clemens Giessen-Jung,Markus Moehler,Andreas Jagenburg,Thomas Kirchner,Thomas Kirchner,Andreas Jung,Andreas Jung,Volker Heinemann,Volker Heinemann +27 more
TL;DR: The FIRE-3 trial as discussed by the authors compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRi plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium
M von Bonin,Friedrich Stölzel,Anja Goedecke,K. Richter,N Wuschek,Kristina Hölig,U. Platzbecker,Thomas Illmer,Markus Schaich,Johannes Schetelig,Alexander Kiani,Rainer Ordemann,Gerhard Ehninger,Marc Schmitz,Martin Bornhäuser +14 more
TL;DR: In this patient cohort, response to MSC transfusion was lower than in the series reported earlier, however, the experience supports the potential efficacy of MSC in the treatment of steroid-refractory aGVHD.